BioCentury | Sep 2, 2013
Company News

Endosense, St. Jude Medical deal

...million) up front, plus up to CHF150 million ($162.1 million) in regulatory milestones. Endosense developed TactiCath...
...with a PMA submission expected by year end. St. Jude said it plans to integrate TactiCath...
BioCentury | Jan 24, 2011
Clinical News

TactiCath: Pivotal trial started

...EndoSense began the U.S. and European pivotal TOCCASTAR trial to compare its TactiCath force-sensing ablation catheter...
...The product has CE Mark approval in the EU. Endosense S.A. , Geneva, Switzerland Product: TactiCath...
Items per page:
1 - 2 of 2